1 The National Institute of Neurological Disorders and

Stroke rt-PA Stroke Study Group. Tissue plasminogen

activator for acute ischemic stroke[J]. N Engl J Med,

1995, 333:1581-1588.

2 Berkhemer OA, Fransen PS, Beumer D, et al. A

randomized trial of intraarterial treatment for acute

ischemic stroke[J]. N Engl J Med, 2015, 372:11-20.

3 Saver JL, Goyal M, Bonafe A, et al. SWIFT PRIME

Investigators. Stent-retriever thrombectomy after

intravenous t-PA vs t-PA alone in stroke[J]. N Engl J

Med, 2015, 372:2285-2295.

4 Campbell BC, Mitchell PJ, Kleinig TJ, et al.

Endovascular therapy for ischemic stroke with

perfusion-imaging selection[J]. N Engl J Med, 2015,

372:1009-1018.

5 Goyal M, Demchuk AM, Menon BK, et al. Randomized

assessment of rapid endovascular treatment of ischemic

stroke[J]. N Engl J Med, 2015, 372:1019-1030.

6 Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy

within 8 hours after symptom onset in ischemic

stroke[J]. N Engl J Med, 2015, 372:2296-2306.

7 中国卒中学会, 中国卒中学会神经介入分会, 中华预防

医学会卒中预防与控制专业委员会介入学组. 急性缺

血性卒中血管内治疗中国指南2015[J]. 中国卒中杂志,

2015, 10:590-606.

8 Powers WJ, Derdeyn CP, Biller J, et al. 2015 American

Heart Association/American Stroke Association

focused update of the 2013 guidelines for the early

management of patients with acute ischemic stroke

regarding endovascular treatment:a guideline for

healthcare professionals from the American Heart

Association/American Stroke Association[J]. Stroke,

2015, 46:3020-3035.

9 Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase

versus tenecteplase for thrombolysis after ischaemic

stroke (ATTEST):a phase 2, randomised, openlabel,

blinded endpoint study[J]. Lancet Neurol, 2015,

14:368-376.

10 Coutts SB, Dubuc V, Mandzia J, et al. Tenecteplasetissue-

type plasminogen activator evaluation for

minor ischemic stroke with proven occlusion[J].

Stroke, 2015, 46:769-774.

11 Albers GA, von Kummer R, Truelsen T, et al. Safety

and eff icacy of desmoteplase given 3-9h af ter

ischaemic stroke in patients with occlusion or highgrade

stenosis in major cerebral arteries (DIAS-3):a

double-blind, randomised, placebo-controlled phase 3

trial[J]. Lancet Neurol, 2015, 14:575-584.

12 Saver JL, Starkman S, Eckstein M, et al. Prehospital

use of magnesium sulfate as neuroprotection in acute

stroke[J]. N Engl J Med, 2015, 372:528-536.13 Llovera G, Hofmann K, Roth S, et al. Results of

a preclinical randomized controlled multicenter

trial (pRCT):Anti-CD49d treatment for acute brain

ischemia[J]. Sci Transl Med, 2015, 7:1-10.

14 Ying Xian Y, Wu J, O’Brien EC, et al. Real world

effectiveness of warfarin among ischemic stroke

patients with atrial fibrillation:observational analysis

from Patient-Centered Research into Outcomes

Stroke Patients Prefer and Effectiveness Research

(PROSPER) study[J]. BMJ, 2015, 351:h3786.

15 O’Brien EC, Greiner MA, Xian Y, et al. Clinical

effectiveness of statin therapy af ter ischemic

stroke:primary results from the statin therapeutic

area of the Patient-Centered Research Into Outcomes

Stroke Patients Prefer and Effectiveness Research

(PROSPER) Study[J]. Circulation, 2015, 132:1404-

1413.

16 Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy

in primary prevention of stroke among adults with

hypertension in China:the CSPPT randomized clinical

trial[J]. JAMA, 2015, 313:1325-1335.

17 Zaidat OO, Fitzsimmons BF, Woodward BK, et al.

Effect of a balloon-expandable intracranial stent

vs medical therapy on risk of stroke in patients

with symptomatic intracranial stenosis:the VISSIT

randomized clinical trial[J]. JAMA, 2015, 313:1240-

1248.

18 Compter A, van der Worp HB, Schonewille WJ, et al.

for the VAST investigators. Stenting versus medical

treatment in patients with symptomatic vertebralartery stenosis:a randomised open-label phase 2

trial[J]. Lancet Neurol, 2015, 14:606-614.

19 Amin-Hanjani S, Du X, Rose -Finnel l L, e t

al. Hemody nami c feat ures of symptomat ic

vertebrobasilar disease[J]. Stroke, 2015, 46:1850-1856.

20 CADISS trial investigators. Antiplatelet treatment

compared with anticoagulation treatment for cervical

artery dissection (CADISS): a randomised trial[J].

Lancet Neurol, 2015, 14:361-367.

21 Sposato LA, Cipr iano LE, Saposnik G, et al.

Diagnosis of atrial fibrillation after stroke and

transient ischaemic attack:a systematic review and

meta-analysis[J]. Lancet Neurol, 2015, 14:377-387.

22 Abdul-Rahim AH, Perez AC, Fulton RL, et al. Risk of

stroke in chronic heart failure patients without atrial

fibrillation:Analysis of the Controlled Rosuvastatin

in Multinational Trial Heart Failure (CORONA) and

the Gruppo Italiano per lo Studio della Sopravvivenza

nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF)

Trials[J]. Circulation, 2015, 131:1486-1494.

23 AVERT Trial Collaboration group. Efficacy and safety

of very early mobilisation within 24h of stroke onset

(AVERT):a randomised controlled trial[J]. Lancet,

2015, 386:46-55.

24 Barzel A, Ketels G, Stark A, et al. Home-based

constraint-induced movement therapy for patients with

upper limb dysfunction after stroke (HOMECIMT):a

cluster-randomised, controlled trial[J]. Lancet Neurol,

2015, 14:893-902.